Radha Mohan Das Agarwal, a senior BJP MLA from Gorakhpur, has compared Serum Institute of India (SII), CEO, Adar Poonawalla with a 'dacoit' and also asked the government to 'acquire' the company under the Epidemic Diseases Act.
Agarwal is upset over anti-coronavirus vaccine pricing.
The SII, on Wednesday, announced a price of Rs 600 per dose for Covishield supplies to private hospitals and Rs 400 per dose to state governments.
"@adarpoonawalla you are worse than a dacoit. @PMOIndia @AmitShah @blsanthosh @drharshvardhan should acquire your factory under epidemic act," the MLA, who is also a doctor, said in a tweet.
The MLA said, "Poonawalla should be allowed maximum profit of Cost + 50 per cent. Cost is Rs 220 so how can he sell at Rs 600 to general public?"
The vaccine maker announced pricing of AstraZeneca shots it manufactures at its Pune facility, following the government decision to open up inoculation to all citizens above 18 years of age.
--IANS
amita/sdr/
(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
)